COYA

アフターアワーズ： 6.11

Coya Therapeutics Inc (COYA)

Relative Volume:

ネットキャッシュフロー:

Coya Therapeutics Inc Stock (COYA) Company Profile

Coya Therapeutics Inc

650.739.3939

12645 MEMORIAL DR., SUITE F1 #305, HOUSTON

COYA's Discussions on Twitter

Coya Therapeutics Inc (COYA) 最新ニュース

Coya Therapeutics Inc (COYA) 財務データ

Coya Therapeutics Inc (COYA)

Coya Therapeutics Inc Stock (COYA) Company Profile

Coya Therapeutics Inc (COYA) 最新ニュース

Research Analysts Issue Forecasts for Coya Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:COYA) - MarketBeat

Coya Therapeutics reports potential Parkinson's treatment breakthrough - Investing.com

Coya Therapeutics reports potential Parkinson's treatment breakthrough - Investing.com India

Coya Therapeutics (NASDAQ:COYA) Now Covered by HC Wainwright - MarketBeat

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease - StockTitan

Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update - MarketBeat

Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation - Yahoo Finance

Coya Therapeutics to Present at Upcoming Healthcare Conferences - StockTitan

Coya Therapeutics promotes Arun Swaminathan to CEO post - The Pharma Letter

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer - citybiz

Coya Therapeutics appoints new CEO, founder shifts role - Investing.com

Coya Therapeutics Names Arun Swaminathan Chief Executive - MarketWatch

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - Manchestertimes

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - StockTitan

Coya Therapeutics, Inc. (NASDAQ:COYA) to Post FY2024 Earnings of ($1.17) Per Share, Chardan Capital Forecasts - MarketBeat

Vanguard Group Inc. Has $8.41 Million Stake in Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat

Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Vanguard Group Inc. - Defense World

Coya Therapeutics, Inc. (NASDAQ:COYA) Forecasted to Earn FY2025 Earnings of ($1.26) Per Share - MarketBeat

Chardan Capital Weighs in on Coya Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:COYA) - Defense World

Frontotemporal Dementia Market to Show Remarkable Growth - openPR

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - Manchestertimes

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - wallstreet:online

COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace

Coya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9% - MarketBeat

Coya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9% - Defense World

Coya Therapeutics Blunders on Test Results - MSN

Coya reports Alzheimer's trial to present at CTAD24 By Investing.com - Investing.com India

Coya reports Alzheimer's trial to present at CTAD24 - Investing.com

Coya reports Alzheimer's trial to present at CTAD24 By Investing.com - Investing.com Canada

Coya Therapeutics Blunders on Test Results - Baystreet.ca

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid - Chronicle-Tribune

Coya Therapeutics files for IP on novel therapy combination - Investing.com

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - StockTitan

Long Term Trading Analysis for (COYA) - Stock Traders Daily

(COYA) Investment Report - Stock Traders Daily

Coya Shares Rise After Next Step to New Study of ALS Treatment - MarketWatch

Coya Therapeutics faces FDA hold on ALS drug study - Investing.com

individual investors who own 58% along with institutions invested in Coya Therapeutics, Inc. (NASDAQ:COYA) saw increase in their holdings value last week - Simply Wall St

Coya Therapeutics faces FDA hold on ALS drug study By Investing.com - Investing.com Canada

Coya Therapeutics (NASDAQ:COYA) Shares Down 2.7% - MarketBeat

Howard Berman, CEO and co-founder of Coya Therapeutics - InnovationMap

3 Houston health tech innovators to know this week - InnovationMap

Trend Tracker for (COYA) - Stock Traders Daily

Coya Therapeutics - The Pharma Letter

Coya extends research collaboration into exosomes from T-cells - Parkinson's News Today

Form 424B3 Coya Therapeutics, Inc. - StreetInsider.com

COYACoya Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with ... - StockTitan

Investor's Toolkit: Key Ratios for Assessing Coya Therapeutics Inc (COYA)'s Performance – DWinneX - The Dwinnex

COYA 302 slows ALS progression, lowers biomarkers: Trial - ALS News Today

COYA 302 slows disease progression, lowers biomarkers: Trial - ALS News Today

Coya Therapeutics Inc (COYA) 財務データ

収益

当期純利益

現金流量

EPS

COYAに似た銘柄